vs
ASSOCIATED BANC-CORP（ASB）与Axsome Therapeutics, Inc.（AXSM）财务数据对比。点击上方公司名可切换其他公司
ASSOCIATED BANC-CORP的季度营收约是Axsome Therapeutics, Inc.的2.0倍（$383.0M vs $191.2M），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs 9.1%）
联合银行集团（Associated Banc-Corp）是美国区域性银行控股公司，总部位于威斯康星州格林贝，深耕美国中西部地区，主营零售银行、商业银行、商业地产贷款、私人银行及特色金融服务，在威斯康星州、伊利诺伊州、明尼苏达州设有220多个营业网点，覆盖100多个社区，还在印第安纳、密歇根等多州设有贷款办事处。
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
ASB vs AXSM — 直观对比
营收规模更大
ASB
是对方的2.0倍
$191.2M
两年增速更快
AXSM
近两年复合增速
9.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $383.0M | $191.2M |
| 净利润 | $119.6M | — |
| 毛利率 | — | — |
| 营业利润率 | — | -33.1% |
| 净利率 | 31.2% | — |
| 营收同比 | — | 57.4% |
| 净利润同比 | 566.6% | — |
| 每股收益（稀释后） | $0.70 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASBAXSM
| Q1 26 | $383.0M | $191.2M | ||
| Q4 25 | $310.0M | $196.0M | ||
| Q3 25 | $305.2M | $171.0M | ||
| Q2 25 | $300.0M | $150.0M | ||
| Q1 25 | $285.9M | $121.5M | ||
| Q4 24 | $270.3M | $118.8M | ||
| Q3 24 | $329.7M | $104.8M | ||
| Q2 24 | $321.8M | $87.2M |
净利润ASBAXSM
| Q1 26 | $119.6M | — | ||
| Q4 25 | $137.1M | $-28.6M | ||
| Q3 25 | $124.7M | $-47.2M | ||
| Q2 25 | $111.2M | $-48.0M | ||
| Q1 25 | $101.7M | $-59.4M | ||
| Q4 24 | $-161.6M | $-74.9M | ||
| Q3 24 | $88.0M | $-64.6M | ||
| Q2 24 | $115.6M | $-79.3M |
营业利润率ASBAXSM
| Q1 26 | — | -33.1% | ||
| Q4 25 | 52.6% | -13.8% | ||
| Q3 25 | 50.5% | -27.0% | ||
| Q2 25 | 46.5% | -24.5% | ||
| Q1 25 | 42.3% | -46.9% | ||
| Q4 24 | -65.8% | -61.1% | ||
| Q3 24 | 32.8% | -59.8% | ||
| Q2 24 | 32.0% | -89.5% |
净利率ASBAXSM
| Q1 26 | 31.2% | — | ||
| Q4 25 | 44.2% | -14.6% | ||
| Q3 25 | 40.9% | -27.6% | ||
| Q2 25 | 37.1% | -32.0% | ||
| Q1 25 | 35.6% | -48.9% | ||
| Q4 24 | -59.8% | -63.1% | ||
| Q3 24 | 26.7% | -61.7% | ||
| Q2 24 | 35.9% | -91.0% |
每股收益（稀释后）ASBAXSM
| Q1 26 | $0.70 | — | ||
| Q4 25 | $0.80 | $-0.55 | ||
| Q3 25 | $0.73 | $-0.94 | ||
| Q2 25 | $0.65 | $-0.97 | ||
| Q1 25 | $0.59 | $-1.22 | ||
| Q4 24 | $-1.10 | $-1.54 | ||
| Q3 24 | $0.56 | $-1.34 | ||
| Q2 24 | $0.74 | $-1.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $305.1M |
| 总债务越低越好 | — | $70.0M |
| 股东权益账面价值 | $5.0B | — |
| 总资产 | $45.6B | $713.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASBAXSM
| Q1 26 | — | $305.1M | ||
| Q4 25 | — | $322.9M | ||
| Q3 25 | — | $325.3M | ||
| Q2 25 | — | $303.0M | ||
| Q1 25 | — | $300.9M | ||
| Q4 24 | — | $315.4M | ||
| Q3 24 | — | $327.3M | ||
| Q2 24 | — | $315.7M |
总债务ASBAXSM
| Q1 26 | — | $70.0M | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $594.1M | — | ||
| Q2 25 | $593.5M | — | ||
| Q1 25 | $591.4M | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $844.3M | — | ||
| Q2 24 | $536.1M | — |
股东权益ASBAXSM
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $88.3M | ||
| Q3 25 | $4.9B | $73.7M | ||
| Q2 25 | $4.8B | $73.1M | ||
| Q1 25 | $4.7B | $53.2M | ||
| Q4 24 | $4.6B | $57.0M | ||
| Q3 24 | $4.4B | $92.9M | ||
| Q2 24 | $4.2B | $102.9M |
总资产ASBAXSM
| Q1 26 | $45.6B | $713.6M | ||
| Q4 25 | $45.2B | $689.8M | ||
| Q3 25 | $44.5B | $669.3M | ||
| Q2 25 | $44.0B | $639.8M | ||
| Q1 25 | $43.3B | $596.7M | ||
| Q4 24 | $43.0B | $568.5M | ||
| Q3 24 | $42.2B | $561.5M | ||
| Q2 24 | $41.6B | $548.2M |
负债/权益比ASBAXSM
| Q1 26 | — | — | ||
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASB
| Net Interest Income | $307.2M | 80% |
| Noninterest Income | $75.9M | 20% |
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
